Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

White House says U.S. can roll out COVID boosters next week

Published 09/17/2021, 12:33 PM
Updated 09/17/2021, 04:41 PM
© Reuters. FILE PHOTO: United States Surgeon General Vivek Murthy delivers remarks during a news conference with White House Press Secretary Jen Psaki at the White House in Washington, U.S., July  15, 2021. REUTERS/Tom Brenner

By Ahmed Aboulenein and Steve Holland

WASHINGTON (Reuters) -The United States is ready to roll out COVID-19 vaccine booster shots next week but only if health regulators approve the plan, White House officials said on Friday.

In August, President Joe Biden said the government would provide boosters in the week of Sept. 20 to address waning vaccine immunity and the highly transmissible Delta variant.

"We've been working through the last few weeks, intensely with our partners, our governors, state, and local health officials, federal pharmacy programs, the community health centers to ensure that we are ready for next week," White House coronavirus response coordinator Jeff Zients said at a briefing.

While some health officials, other countries and vaccine makers say boosters are needed, many experts disagree, including two top scientists at the Food and Drug Administration who are leaving the agency later this year.

Surgeon General Vivek Murthy told reporters boosters will be available once the FDA and the Centers for Disease Control and Prevention approve the plan. Critics have said the Biden administration's booster plan is putting pressure on scientists or getting ahead of their evaluations.

"We have always said that this initial plan would be contingent on the FDA and the CDC's independent evaluation. We will follow that evaluation and their recommendations. We will make sure our final plan reflects it," he said.

The plan was not announced in advance to create pressure, he added, but to create transparency and to be better prepared.

Murthy was among eight top U.S. health officials including the FDA and CDC chiefs who have said boosters are necessary.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

A panel of independent expert advisers to the FDA is debating whether Americans should receive a booster dose of the Pfizer/BioNTech vaccine and was set to vote later on Friday.

The CDC's Advisory Committee on Immunization Practices will meet next week to discuss boosters.

The United States had an average of 146,000 COVID-19 cases, 11,165 hospitalizations and 1,448 deaths in its most recent seven-day period, CDC Director Rochelle Walensky said on Friday.

The CDC will invest $2.1 billion to protect patients and healthcare workers from COVID-19 and future infectious diseases, she said. The funding comes from the $1.9 trillion American Rescue Plan Biden passed in March to address the pandemic.

So far 89% of active U.S. military troops received at least one vaccine shot, Zients said, up from 76% three weeks ago.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.